28.11.2011

5 outstanding companies at the next Swiss Venture Day

Femtotools, Iprova and 3 medtech companies – Advanced Urology Solutions, Aeon, Pearltec – will present at the next Swiss Venture Day on December 7th.

Quantity and Quality of Swiss start-ups are improving. At the same time more and more awards are given to young companies. It is not easy to keep an overview of all startups and select the most promising. CTI Invest, the Swiss Venture Platform therefore presents selected startups four times a year on the Swiss Venture Days.

The next Venture Day will have a focus on medical technology. 3 of the presenting companies are from this industry.

  • Advanced Urology Solutions is a very young company headed by Jean-Jacques Becciolini who is also the co-founder and Vice-Chairman of Swiss Medical Solutions, a company focusing on urine tests.
  • Aeon Scientific is developing a tool for surgeons. It allows them to navigate a catheter with great precision during a catheter ablation.
  • Pearltec is a well known young company that is planning the second step of its development. The company produces devices for the comfortable positioning, bedding and immobilization of patients during complex and costly imaging procedures such as CT or MRI

The 2 other companies are from different industries

  • Femtotools has just launched a micromechanical testing and assembly system platform. It allows for sophisticated micromechanical testing or the microassembly of small objects in an intuitive and user-friendly way.
  • Iprova is an early stage company led by the renowned IP expert Julian Nolan. The startup is developing a new, hugely disruptive, technology. The team is currently conducting pre-launch trials with some of the world's leading corporations.

Categories

Capital, CTI, Investor, Start-up

Subscribe Newsletter


Stay up2date!

Get the startupticker.ch App
for your Phone or your Tablet!
   

Swiss start-up turns to the Nasdaq

Last year Auris Medical raised more than CHF47 million in venture capital for further growth. This was the largest round of financing in Switzerland in 2013. The company has two drugs in development: an injection for tinnitus and a drug for hearing loss in the inner ear. The tinnitus medication has already started the third and most expensive stage of development, the phase III trial. The Basel company, which has its headquarters in Zug, intends to raise the necessary capital on the Nasdaq: the IPO should bring Auris a total of $95 million in new money.

Partners

Sponsors